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Abstract Head and neck cancer is a capricious disease that varies greatly in its clinical behavior. 
The development of biomarkers that can distinguish between biologically aggressive and indolent 
tumors has been a long term goal of our laboratories. Predictive markers applicable to biopsy 
specimens should facilitate clinical management through early identification of patients a t  greatest 
risk for early relapse or metastatic spread. Two prominent cell surface markers that we identified by 
raising monoclonal antibodies to squamous cell carcinomas are blood group antigens and the A9 anti- 
genlcr6P4 integrin. Both of these markers are abnormally displayed in squamous cancers of the head 
and neck and serve as indicators of early relapse. Loss of blood group antigen expression is a stronger 
single indicator than is overexpression of the 01604 integrin. However, use of both markers together 
is a stronger predictive indicator than is either alone. We know little about the function of the blood 
group antigens in squamous cells except that the mature antigens are associated with differentiation. 
Similarly, the function of the a604 integrin is also not fully understood. Integrin a604 is thought to 
serve as an extracellular matrix receptor, but its ligand has not been confirmed. In resting epithelium, 
the a604 integrin is polarized to the basal aspect of the basal cell as a component of the hemidesmo- 
some, the anchoring structures of the epithelia. This basal polarization is lost in migrating normal 
squamous cells and squamous carcinomas. Tyrosine phosphorylation of the 04 subunit is absent or 
greatly reduced in malignant cells and this may be a critical signal for subcellular localization of a604 
and cell anchoring. On the basis of our current experimental results, we postulate that tyrosine 
phosphorylation of the 04 subunit is a reversible signal that regulates cell migration in normal and 
malignant cells, and may therefore be an important initial event in the metastatic cascade. 
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Abnormal expression of normal antigens is a 
characteristic of squamous carcinomas. We 
raised monoclonal antibodies against cell lines 
cultured from head and neck squamous carcino- Address correspondence to Dr. Thomas E. Carey, Labora- 
University of Michigan, 1301 East Ann Street, Ann markers that are Prominently and abnormally 
Arbor, MI 48109-0506. expressed. These antibodies, UM-G10 and 
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UM-AS, define the H-type-2 blood group antigen 
[l]  and the a604 integrin, respectively [2,3]. 
The H-type-2 antigen is a carbohydrate struc- 
ture that serves as the acceptor site for the A 
and B blood group antigens. In the epithelium, 
the H-type-2 antigen is normally expressed only 
on the basal epithelial cells of persons who are 
either blood group A or B, but it is expressed 
throughout the epithelium of blood group 0 
individuals. In many cases, squamous carcino- 
mas express this antigen strongly even if the 
donor is blood type A or B [1,4,5]. In fact, over- 
expression of the H-type-2 precursor in tumors 
often goes hand-in-hand with absence of the 
mature form. The antigen defined by the 
UM-A9 antibody is also strongly expressed by 
most squamous carcinomas even though this 
marker is more restricted in its expression in 
normal epithelium, where it is present only on 
the basal surface of the basal cells. Examples of 
the A9 antigen and blood group A antigen dis- 
tribution in normal tongue and in an early 
invasive squamous cancer in a blood type A 
patient are shown in Figure 1. 
Clues that these structures might serve as 
biomarkers of aggressive malignant behavior 
came initially from studies of cell lines cultured 
from primary and metastatic tumors in the 
same individuals, where the expression of the 
H-type-2 antigen [1,6] and the A9 antigen [2,6] 
were both more prominent on the metastatic or 
recurrent tumor cell lines than on the primary 
tumor cell lines. Furthermore, loss of blood 
group antigen expression had been shown to  be 
Fig. 1. Photomicrographs of immunoperoxidase stained frozen sections of tongue tissue from a patient 
with early invasive squamous cell cancer. (a) Section stained with UM-A9 antibody to the a6p4 integrin. 
Note that a6p4 integrin expression is limited to basal epithelial cells in the normal tissue but that the tumor 
is stained from its epithelial surface to its invasive edge. (b) Adjacent section stained with a monoclonal 
antibody specific for blood group A. Note that in this section blood group A is expressed throughout the 
normal epithelium but is absent in the region of the tumor. (Original magnification 40 x 1 Reprinted from 
Carey et a/. 14) with permission of Mosby Year Book, Inc. 
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associated with metastasis in cervical carcinoma 
[7] and invasive behavior in bladder cancer [8 ] .  
We analyzed blood group and A9 antigen ex- 
pression in a series of tumors from patients 
with previously untreated head and neck cancer 
and reported that overexpression of A9 antigen 
and loss of mature blood group antigens were 
each associated with early relapse [4,5]. When 
we performed a subsequent analysis with longer 
follow-up in the same group of head and neck 
cancer patients [91, we found that as a single 
variable, loss of blood group antigen is a stron- 
ger predictive marker for shortened, disease-free 
survival (Fig. 2) than is overexpression of A9 
antigedcy6P4 integrin. However, when both 
variables are combined it is possible to  separate 
patients into three prognostic groups (Fig. 3). 
These observations have led to  several impor- 
tant research questions: Why are these markers 
associated with biological behavior in vivo? How 
can we best use these markers clinically? Can 
they be used for selecting patients for therapy? 
Can they be used to monitor response to chemo- 
preventive therapy? The answers to  these ques- 
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tions may become clear once the functional 
significance of the altered antigen expression is 
known. 
Very little is known about the function of the 
blood group antigens in epithelia, making it 
difficult to  determine why these are strong 
prognostic markers. One possibility is that as 
squamous epithelial cells mature and differenti- 
ate, they display the mature blood group anti- 
gen on the cell surface. Thus, failure t o  express 
mature blood group antigens may indicate failed 
maturation and a relatively undifferentiated 
phenotype. An alternative hypothesis is that 
blood group antigens are part of cell-to-cell 
adhesion structures and loss of these structures 
facilitates metastatic behavior. Since altered 
expression of blood group antigens and associa- 
tion of aberrant expression with prognosis has 
been noted by several investigators, including 
the recent report by Lee et al. [lo] that expres- 
sion of blood group A antigen in lung tumors is 
a favorable prognostic indicator in non-small 
cell lung cancer, it is clear that much more 
work on this subject is indicated. 
DISEASE-FREE SURVIVAL ACCORDING TO 
TUMOR EXPRESSBON OF BLOOD GROUP (ABH) 
N FAILED MEDIAN 
............. Reta~n 43 23 32.2months 
Loss 25 19 8.1 months 
p=.046 
Fig. 2. Disease-free survival according to tumor expression of ABH blood group. Disease-free interval was 
significantly longer in patients whose tumor retained blood group expression compared to those who had 
lost expression. Reprinted from Wolf et a/. (91. 
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Fig. 3. Disease-free survival according to intensity of A9/016p4 integrin expression and loss of blood group 
(ABH) expression in the patients' tumors. The longest median survival was associated with tumors 
exhibiting low A9/016p4 expression and retained blood group expression. Reprinted from Wolf et a/. [9]. 
a6 AND fl4 INTEGRIN SUBUNIT 
EXPRESSION IN MALIGNANT CELLS 
Van Waes et al. [3] showed by immunoprecip- 
itation and preclearing experiments that the A9 
antigen was a heterodimeric complex of two 
protein chains, an alpha subunit (a61 and a beta 
subunit @4), typical of the integrin family of 
cell surface receptors. Overexpression of this 
integrin appears to  be a common factor in sev- 
eral epithelial cancers since it was discovered 
independently as a tumor antigen by several 
groups who raised antibodies against other 
tumors. For example, Kennel and co-workers 
[ll] described the TSP-180 antigen in murine 
lung carcinoma, a marker that is overexpressed 
on metastatic but not non-metastatic clones of 
the Lewis lung carcinoma cell line. TSP-180 was 
later shown to  be the a6p4 integrin [12]. These 
authors also demonstrated that human lung 
carcinomas exhibit aberrant expression of the 
a6P4 integrin [131. Similarly, Kajiji et al. [14] 
raised antibodies against pancreatic carcinomas 
that identify the a664 integrin. Thus, the a604 
integrin is a prominent immunogenic determi- 
nant on many epithelial cancers. 
In our own group, the BQ16 monoclonal 
antibody was raised against human bladder 
carcinoma cells 1151. UM-A9 and BQ16 showed 
strong similarities in the staining of normal 
epithelia, but differed in their reactivity with 
certain bladder cancer cell lines. At first we felt 
that these antibodies identified different struc- 
tures, until one of us (ML) suggested that the 
antibodies might identify different subunits of 
the a6p4 integrin. If so, tumors that were posi- 
tive for BQ 16 but negative for UM-A9 reactivity 
might express only one of the subunits. In fact, 
this hypothesis was correct. BQ16 identifies the 
a6 subunit and UM-A9 identifies either the 64 
subunit alone or the intact a604 complex 1151. 
Since it appears that p4 is expressed only in a 
complex with a6, it is difficult to  rule out the 
possibility that the UM-A9 epitope is deter- 
mined by both chains. An experiment that com- 
pares the two antibodies for their ability to 
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Fig. 4. Pulse-chase immunoprecipitation experiment com- 
paring proteins precipitated from the same cell extracts by 
monoclonal antibodies UM-A9 and BQ16. UM-SCC-38 cells 
were labeled with 35S-methionine for 15 or 30 rnin and then 
either lysed or refed with medium containing cold methio- 
nine and incubated for additional periods of time ranging 
from 30 min to 24 hr. The labeled cells were iysed and 
immunoprecipitated with either UM-A9 or BQ16 and pro- 
tein-A sepharose beads. The immunoprecipitates were 
precipitate the a604 integrin is shown in Fig- 
ure 4. This is a pulse-chase labeling experiment 
in which UM-SCC-38 cells were incubated in 
[35S]-methionine for 15-30 min and then placed 
in medium with unlabeled methionine. Repli- 
cate plates were harvested at 15 min (lanes 1, 
71, 30 min (lanes 2, 81, and then at intervals of 
cold label chase of 30 min (lanes 3, 9), 1 hr 
(lanes 4, lo), 4 hr (lanes 5, 11) and 24 hr 
(lanes 6, 12). Proteins shown in lanes 1-6 were 
immunoprecipitated with BQ16 and those load- 
ed in lanes 7-12 were precipitated with UM-AS. 
The figure shows that at the early time points, 
the only labeled protein precipitated by BQ16 is 
a 140 kD protein that corresponds to  the unpro- 
cessed intact polypeptide form of the a6 subunit 
[3,12]. Similarly, at the earliest time points, 
UM-A9 precipitates a 205 kD protein corres- 
ponding t o  the intact mature 04 subunit with a 
lesser amount of the a6 precursor. With addi- 
tional time after labeling, precipitates of both 
antibodies contain the labeled 205 kD 04 sub- 
unit and the processed 125 kD heavy chain of 
the a6 subunit (lanes 4, 5, 6 and 10, 11, 12). At 
later time points, the UM-A9 precipitates 
(lanes 9-12) also contain 175 and 150 kD pro- 
teolytic cleavage products of the 04 chain [3,12, 
washed several times and then boiled in SDS buffer under 
reducing conditions, separated by polyacrylamide gel 
electrophoresis, and analyzed by autoradiography. Label- 
ing conditions: 15 min pulse only-lanes 1,7; 30 min pulse 
only-lanes 2,8; 30 min pulse plus 30 min cold 
chase-lanes 3,Q; 1 hr cold chase-lanes 4,lO; 4 hr cold 
chase-lanes 5,11; 24 hr cold chase-lanes 6,12. (Repro- 
duced from [15], with permission of the publisher.) 
211. This experiment supports the hypothesis 
that BQ16 binds to  the a6 subunit and that 
UM-A9 binds either to  the 04 subunit or the 
intact a604 heterodimer. Since the a6 subunit 
can also combine with the 01 subunit, those 
bladder carcinoma cell lines that are positive for 
BQ16 staining and negative for UM-A9 staining 
most likely express the a601 integrin but not 
the a604 integrin. The functional significance of 
this difference in integrin subunit expression is 
not yet known. Thus far we have not observed 
any examples of squamous cancers that are a6 
positive and 04 negative. 
a6 AND fl4 INTEGRIN EXPRESSION 
IN NORMAL EPITHELIUM 
On normal epithelia, BQ16 and UM-A9 have 
identical staining patterns along the basal sur- 
face of skin, mucosa, and transitional epithelia 
(Fig. 5). In Figure 5 ,  the same section of normal 
skin is co-stained with UM-A9 and BQ16. Since 
UM-A9 is an IgG2a antibody and BQ16 is an 
IgGl antibody, the binding could be detected 
with one secondary antibody specific for IgG2a, 
labeled with fluorescein, and another antibody 
specific for IgGl labeled with rhodamine. 
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Fig. 5. lmmunofluorescence staining of frozen sections of normal skin with UM-A9 and BQ16 antibodies. 
The section was incubated with a mixture of UM-A9 and BQ16, washed and incubated with a mixture of 
secondary antibodies to IgG2a (labeled with fluorescein) and IgG1 (labeled with rhodamine). The sections 
were evaluated for fluorescence under a 50 x objective. The same field was photographed twice, once with 
a filter for green fluorescence and once with a filter for red fluorescence. (a) Linear staining of the basal 
surface of the epithelium by UM-AS. Note also staining of some small vessels and nerve fibers in the 
dermis. (b) Linear staining of the basal surface of the epithelium by BQ16. Note that this antibody also 
stains small vessels in the dermis. 
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ROLE OF a6/34 INTEGRIN IN THE 
ANCHORING PROCESS 
The location of a604 along the basement 
membrane suggests that this integrin is in- 
volved in the anchoring process in normal epi- 
thelia. Ultrastructural electron microscopic 
studies by several groups [16-181 have shown 
that the a604 integrin is clustered in the region 
of the hemidesmosome in normal epithelia, 
offering further support for the concept that 
a604 is involved in the anchoring process. How- 
ever, expression of the a604 integrin is depolar- 
ized [19,20] in tumors and in normal keratino- 
cytes growing and migrating under wound heal- 
ing conditions in which hemidesmosomes do not 
form until migration is completed [19]. An ex- 
ample of the peripheral non-basal distribution 
of the a604 integrin in normal keratinocytes 
grown in basal keratinocyte medium, a condi- 
tion that fosters cell migration, and to  some 
extent, mimics the wound healing response, is 
shown in Figure 6a. Basal polarization of the 
integrin occurs in normal keratinocytes grown 
in the same basal keratinocyte medium to 
which 1.4 mM calcium and 10" M retinoic acid 
were added, as shown in Figure 6b. The Swiss- 
cheese pattern of a604 integrin expression not- 
ed under these conditions is visually similar to  
the staining pattern observed with antibodies to  
other hemidesmosomal components in the hemi- 
desmosome-forming 804G cell line [21]. Based 
on these and other observations, we postulate 
that the a604 integrin serves two roles, one in 
migration where high expression is accompanied 
by peripheral distribution, and a second in an- 
choring where the integrin becomes localized to  
the basal surface as it is in normal epithelia. 
The mechanisms that control the distribution of 
the a604 integrin on the cell surface are not 
known; one possibility is that changes in the 
phosphorylation state of the 0 subunit may be 
important [201. 
NROSINE PHOSPHORYIATION OF THE 
fl4 SUBUNIT 
Falcioni et al. [22] reported that the 0 sub- 
unit of a6p4 integrin is phosphorylated on ser- 
ine, threonine and tyrosine residues in murine 
Lewis lung carcinoma. The amino acid sequence 
of the cytoplasmic domain of human 04 protein 
contains numerous consensus phosphoserine 
and phosphothreonine acceptor sites, as well as 
a single phosphotyrosine site. We previously 
reported that the degree of phosphorylation of 
the 04 subunit varied with culture conditions 
[20], and that the incorporation of inorganic 
phosphate into 04 protein increased under cul- 
ture conditions associated with induction of 
Fig. 6. lmmunofluorescence photomicrographs of normal keratinocytes growing in vifro and stained with 
the UM-A9 antibody. (a) Keratinocytes grown in basal keratinocyte medium without epidermal growth 
factor. Note that the olsp4 integrin is distributed on the peripheral margins of the cells and in bright 
punctate spots on microfilopodia in these migrating cells. (b) Keratinocytes grown in basal keratinocyte 
medium to which 1 p M  retinoic acid and 1.4 mM calcium chloride had been added 24 hr previously. In 
this culture the cells have migrated into colonies and the ~ 6 B 4  integrin expression is now mostly polarized 
to the basal surface in a "Swiss cheese" pattern. 
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keratinocyte differentiation, and decreased in 
the presence of retinoic acid, which stimulates 
cell migration and DNA synthesis in the ab- 
sence of calcium. Our initial phosphoamino acid 
analysis experiments revealed only phosphoser- 
ine and phosphothreonine modifications on 04. 
As there is only one consensus phosphotyrosine 
site, it is likely that this would be more difficult 
to  detect, especially since it might be labile to  
protein tyrosine phosphatase cleavage. To exam- 
ine tyrosine phosphorylation of the 04 integrin, 
we used the protein tyrosine phosphatase inhib- 
itor sodium orthovanadate and western blotting 
with antiphosphotyrosine antibodies. Normal 
cells and tumor cells were treated with 100 pM 
vanadate for periods ranging from 0 to 24 hr. 
The cells were lysed, immunoprecipitated with 
UM-A9 antibody, subjected t o  electrophoresis, 
transferred t o  nitrocellulose, and probed with 
an antiphosphotyrosine antibody (Upstate Bio- 
technology Inc., Lake Placid, NY). No tyrosine 
phosphorylation was detected at 0 hr, but a 
doublet of phosphotyrosine-positive bands corre- 
sponding to  the 205 kD 04 protein and a higher 
molecular weight band of - 230 kD was detect- 
ed in the a604 immunoprecipitates from normal 
keratinocytes treated with vanadate for 24 hr. 
This signal was not present in lysates from 
identically treated UM-SCC-38 tumor cells 
(Fig. 7). Similarly, keratinocytes treated with 
vanadate undergo a spreading response (Fig. 8) 
that was not observed in the UM-SCC-38 cells 
under the same conditions. It also appears that 
vanadate-induced spreading may block the mi- 
gration of keratinocytes into colonies typically 
induced in keratinocyte cultures by the addition 
of 1.4 mM calcium as shown in Figure 8. 
The full significance of these observations is 
not known. Our current interpretation is that 
phosphorylation and dephosphorylation of tyro- 
sine in the 04 integrin subunit is a dynamic 
process in cultured keratinocytes. To observe a 
strong 04 phosphorylation signal, it is necessary 
to  block dephosphorylation with vanadate for 
24 hr. This suggests that most of the 04 protein 
is not phosphorylated on tyrosine in actively 
dividing and migrating cells. Treatment of nor- 
mal cells with vanadate also results in inhibi- 
tion of migration and induction of spreading, 
suggesting that tyrosine phosphorylation on 04 
and cessation of migration are related. In the 
UM-SCC-38 tumor cell cultures, 24 hr of treat- 
V 0 4 + - -  + + + - + + +  
Ant!-phosphotyrosine + + + - - + +  + + +  
Cell NK NK ,:is NK SCC SCC SCC Normal her*tlnOCyfeS 
type 
10 25 50 (ugllane) 
UM-A9 immunoprecipitates whole cell lysate 
Fig. 7. Chemiluminescence staining with anti-phosphoty- 
rosine antibody on a western blot of proteins immunopre- 
cipitated from normal and malignant keratinocytes by 
UM-A9 antibody. Normal adult human keratinocytes and 
UM-SCC-38 cells were grown in keratinocyte growth medi- 
um until 24 hr before harvest, when 100 pM sodium ortho- 
vanadate was added to some cultures as indicated on the 
figure. The cells were lysed, and the a6p4 integrin was 
precipitated with UM-A9 antibody and protein-A sepharose 
beads after which the beads were washed, boiled in SDS 
reducing buffer, and the immunoprecipitates separated by 
polyacrylamide gel electrophoresis and transferred to 
nitrocellulose. The blots were incubated with antiphospho- 
tyrosine antibody as indicated on the figure and developed 
using the enhanced chemiluminescence technique. Note 
that the only phosphotyrosine signal detected was a dou- 
blet at 205-230 kD corresponding to the p4 protein and a 
slightly higher molecular weight band shown in lane A. The 
other bands are from secondary antibody binding to the 
reduced UM-A9 immunoglobulins as shown in IaneC 
where only the UM-A9 antibody and the protein A beads 
but no cell lysate were loaded. The same pattern was 
obtained in lanes D and E where no antiphosphotyrosine 
antibody was added to the blot. Lane F shows that the 
tumor cells fail to phosphorylate p4 on tyrosine. Lanes H, 
I, J are whole cell lysates showing the range of phospho- 
tyrosine-modified proteins in normal keratinocytes. 
ment with 100 pM vanadate had no effect on 
either the morphology of the cells (not shown) 
or on the 04 phosphotyrosine modification 
(Fig. 8). This suggests that failure to  phosphor- 
ylate the 04 tyrosine or rapid dephosphorylation 
of 04, may correspond to  the failure of tumor 
cells to  stop migrating. The basis for this differ- 
ence between normal and malignant cells is not 
known. Tumor cells may have an abnormality 




Fig. 8. Photomicrograph showing the effects of calcium 
and vanadate on normal keratinocyte cultures. Keratino- 
cytes growing in complete keratinocyte growth medium 
were fed as indicated on the figure with either fresh medi- 
um, medium containing 100 pM Na,VO, medium contain- 
ing 1.4 mM CaCI,, or both, 24 hr before this photograph 
was taken. Note that cells fed with calcium migrate into 
colonies. Cellsfed with vanadate exhibit a spread morphol- 
ogy, and cells fed with both agents exhibit primarily the 
spread morphology without much evidence of migration 
into colonies. 
that affects either phosphorylation or dephos- 
phorylation of the single tyrosine acceptor site 
(tyrosine 1649) in 04 protein. Thus, in tumor 
cells, the tyrosine kinase that phosphorylates 
tyrosine 1649 may be lost or inactive. There 
may be a mutation that affects the acceptor site 
in the 04 protein or there may be overexpres- 
sion or aberrant activity of the protein tyrosine 
phosphatase that dephosphorylates tyrosine 
1649. Kennel et al. [23] have reported that 
certain lung cancers lack the distal cytoplasmic 
domain of the 04 subunit containing the phos- 
phorylation site. They postulated that this may 
have functional significance. Preliminary experi- 
ments with UM-SCC-38 cells indicate that this 
is not the case in these cells. Treatment with 
3-9-fold higher vanadate concentrations does 
lead t o  04 tyrosine phosphorylation and changes 
in cell morphology similar to  those induced in 
normal keratinocytes at lower concentrations. 
This implicates increased protein tyrosine phos- 
phatase activity as a basis for the decreased 
tyrosine phosphorylation of 04 observed in 
squamous cell carcinoma. 
Failure to  phosphorylate tyrosine or  rapid 
dephosphorylation of tyrosine, in the 04 sub- 
unit, may be a key difference between normal 
and malignant keratinocytes. We propose that 
phosphorylation of tyrosine 1649 may be re- 
quired for the anchoring process to  occur. The 
location of the a604 integrin in the hemidesmo- 
some in normal skin and mucosa suggests that 
this integrin is involved in, and perhaps critical 
to, hemidesmosome assembly. In fact, tyrosine 
phosphorylation of 04 may create a high affinity 
protein binding site that induces hemidesmo- 
some formation. Since formation of hemidesmo- 
somes may be necessary for differentiation, 
inhibition of hemidesmosorne formation by 
increased tyrosine phosphatase activity could 
block differentiation and increase migratory 
behavior. In normal wound healing this would 
allow for keratinocyte migration and re-epitheli- 
alization; however, in tumor cells, alteration in 
this process could predispose cells to metastatic 
behavior. It will be important t o  determine if 
integrin phosphorylation can be regulated by 
chemopreventive agents, since this could inhibit 
abnormal growth and migration. 
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